<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Use of vasopressors and inotropes</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Use of vasopressors and inotropes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Use of vasopressors and inotropes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott Manaker, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michelle Ng Gong, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Vasopressors are a powerful class of drugs that induce vasoconstriction and thereby elevate mean arterial pressure (MAP). Vasopressors differ from inotropes, which increase cardiac contractility; however, many drugs have both vasopressor and inotropic effects. Although many vasopressors have been used since the 1940s, few controlled clinical trials have directly compared these agents or documented improved outcomes due to their use [<a href="#rid1">1</a>]. Thus, the manner in which these agents are commonly used largely reflects expert opinion, animal data, and the use of surrogate end points, such as tissue oxygenation, as a proxy for decreased morbidity and mortality.</p><p>Basic adrenergic receptor physiology and the principles, complications, and controversies surrounding use of vasopressors and inotropes for treatment of shock are presented here. Issues related to the differential diagnosis of shock and the use of vasopressors in patients with septic shock are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1594.html" rel="external">"Definition, classification, etiology, and pathophysiology of shock in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PHYSIOLOGIC MECHANISMS OF VASOCONSTRICTION</span><span class="headingEndMark"> — </span>The main categories of adrenergic receptors relevant to vasopressor activity are the alpha-1, beta-1, and beta-2 adrenergic receptors, as well as the <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> receptors [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Alpha adrenergic</span><span class="headingEndMark"> — </span>Activation of alpha-1 adrenergic receptors, located in vascular walls, induces significant vasoconstriction. Alpha-1 adrenergic receptors are also present in the heart and can increase the duration of contraction without increased chronotropy. However, clinical significance of this phenomenon is unclear [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Beta adrenergic</span><span class="headingEndMark"> — </span>Beta-1 adrenergic receptors are most common in the heart and mediate increases in inotropy and chronotropy with minimal vasoconstriction. Stimulation of beta-2 adrenergic receptors in blood vessels induces vasodilation.</p><p class="headingAnchor" id="H5"><span class="h2">Dopamine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">Dopamine</a> receptors are present in the renal, splanchnic (mesenteric), coronary, and cerebral vascular beds; stimulation of these receptors leads to vasodilation. A second subtype of dopamine receptors causes vasoconstriction by inducing <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> release.</p><p class="headingAnchor" id="H2432921791"><span class="h2">Calcium sensitizers</span><span class="headingEndMark"> — </span>Some agents increase the sensitivity of the myocardial contractile apparatus to calcium, causing an increase in myofilament tension development and myocardial contractility (eg, pimobendan, levosimendan). These agents have additional pharmacologic properties, such as phosphodiesterase inhibition, which may increase inotropy and vasodilation and contribute significantly to their clinical profile, the details of which are discussed separately.</p><p class="headingAnchor" id="H3743046761"><span class="h2">Angiotensin</span><span class="headingEndMark"> — </span>Angiotensin receptors (AT<sub>1</sub> and AT<sub>2</sub>) are G-coupled protein receptors with angiotensin II as their ligand. Angiotensin II is a vasoconstrictor that is part of the renin-aldosterone-angiotensin (RAAS) system. When receptors are stimulated, cytosolic calcium concentration increases to mediate vasoconstrictive effects as well as aldosterone and <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a> secretion [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H6"><span class="h1">PRINCIPLES</span><span class="headingEndMark"> — </span>Hypotension may result from hypovolemia (eg, exsanguination), pump failure (eg, severe medically refractory heart failure or shock complicating myocardial infarction), or a pathologic maldistribution of blood flow (eg, septic shock, anaphylaxis). (See  <a class="medical medical_review" href="/z/d/html/1594.html" rel="external">"Definition, classification, etiology, and pathophysiology of shock in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3488.html" rel="external">"Inotropic agents in heart failure with reduced ejection fraction"</a>.)</p><p>Vasopressors are indicated for a decrease of &gt;30 mmHg from baseline systolic blood pressure, or a mean arterial pressure &lt;60 mmHg when either condition results in end-organ dysfunction due to hypoperfusion [<a href="#rid6">6</a>]. Hypovolemia should be corrected prior to the institution of vasopressor therapy [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/1607.html" rel="external">"Treatment of severe hypovolemia or hypovolemic shock in adults"</a>.)</p><p>The rational use of vasopressors and inotropes is guided by three fundamental concepts:</p><p class="bulletIndent1"><span class="glyph">●</span>One drug, many receptors – A given drug often has multiple effects because of actions upon more than one receptor. As an example, <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> increases cardiac output by beta-1 adrenergic receptor activation; however, it also acts upon beta-2 adrenergic receptors and thus induces vasodilation and can cause hypotension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dose-response curve – Many agents have dose-response curves, such that the primary adrenergic receptor subtype activated by the drug is dose-dependent. As an example, <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> stimulates beta-1 adrenergic receptors at doses of 2 to 10 mcg/kg per minute, and alpha adrenergic receptors when doses exceed 10 mcg/kg per minute.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Direct versus reflex actions – A given agent can affect mean arterial pressure (MAP) both by direct actions on adrenergic receptors and by reflex actions triggered by the pharmacologic response. Norepinephrine-induced beta-1 adrenergic stimulation alone normally would cause tachycardia. However, the elevated MAP from <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a>'s alpha-adrenergic receptor-induced vasoconstriction results in a reflex decrease in heart rate. The net result may be a stable or slightly reduced heart rate when the drug is used.</p><p></p><p class="headingAnchor" id="H7"><span class="h1">PRACTICAL ISSUES</span><span class="headingEndMark"> — </span>Use of vasopressors and inotropic agents requires attention to a number of issues:</p><p class="headingAnchor" id="H8"><span class="h2">Volume resuscitation</span><span class="headingEndMark"> — </span>Adequate intravascular volume resuscitation, when time permits, is crucial prior to the initiation of vasopressors. As an example, most patients with septic shock require at least 2 liters of intravenous fluid in order for vasopressors to be maximally effective [<a href="#rid8">8</a>]. Vasopressors will be ineffective or only partially effective in the setting of coexistent hypovolemia.</p><p>Fluids may be withheld in patients with significant pulmonary edema due to the acute respiratory distress syndrome (ARDS) or heart failure (HF). In patients with a pulmonary artery catheter, pulmonary capillary wedge pressures (PCWP) of 18 to 24 mmHg are recommended for cardiogenic shock [<a href="#rid9">9</a>], and 12 to 14 mmHg for septic or hypovolemic shock [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/1595.html" rel="external">"Pulmonary artery catheterization: Interpretation of hemodynamic values and waveforms in adults"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Selection and titration</span><span class="headingEndMark"> — </span>Choice of an initial agent should be based upon the suspected underlying etiology of shock (eg, <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> in cases of cardiac failure without significant hypotension, <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> for anaphylactic shock). The dose should be titrated up to achieve effective blood pressure or end-organ perfusion as evidenced by such criteria as urine output or mentation. If maximal doses of a first agent are inadequate, then a second drug should be added to the first. In situations where this is ineffective, such as refractory septic shock, anecdotal reports describe adding a third agent, although no controlled trials have demonstrated the utility of this approach.</p><p class="headingAnchor" id="H10"><span class="h2">Route of administration</span><span class="headingEndMark"> — </span>Vasopressors and inotropic agents should be administered through an appropriately positioned central venous catheter, if available. This facilitates more rapid delivery of the agent to the heart for systemic distribution and eliminates the risk of peripheral extravasation. When a patient does not have a central venous catheter, vasopressors and inotropic agents can be administered through an appropriately positioned peripheral intravenous catheter temporarily, until a central venous catheter is inserted [<a href="#rid11">11,12</a>]. (See  <a class="medical medical_review" href="/z/d/html/8180.html" rel="external">"Central venous catheters: Overview of complications and prevention in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8194.html" rel="external">"Central venous access in adults: General principles"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Tachyphylaxis</span><span class="headingEndMark"> — </span>Responsiveness to these drugs can decrease over time due to tachyphylaxis. Doses must be constantly titrated to adjust for this phenomenon and for changes in the patient's clinical condition [<a href="#rid13">13,14</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Hemodynamic effects</span><span class="headingEndMark"> — </span>Mean arterial pressure (MAP) is influenced by systemic vascular resistance (SVR) and cardiac output (CO). In situations such as cardiogenic shock, elevating SVR increases afterload and the work of an already failing heart, thus potentially lowering CO. Some authors recommend keeping the SVR approximately 700 to 1000 dynes x sec/cm<sup>5</sup> to avoid excessive afterload and to minimize complications from profound vasoconstriction (<a class="calc calc_professional" href="/z/d/html/13460.html" rel="external">calculator 1</a>) [<a href="#rid15">15</a>]. However, there is no consensus regarding an ideal target cardiac index (CI). Studies that have attempted to maintain a supraphysiologic CI of &gt;4 to 4.5 L/minute per m<sup>2</sup> have not shown consistent benefit [<a href="#rid16">16,17</a>]. (See  <a class="medical medical_review" href="/z/d/html/1623.html" rel="external">"Oxygen delivery and consumption"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Subcutaneous delivery of medications</span><span class="headingEndMark"> — </span>Critically ill patients often receive subcutaneously injected medications, such as heparin and insulin. The bioavailability of these medications can be reduced during treatment with vasopressors due to cutaneous vasoconstriction.</p><p>This was demonstrated in a study that monitored plasma factor Xa levels in three groups of hospitalized patients following the initiation of prophylactic low molecular weight heparin [<a href="#rid18">18</a>]. Patients who required vasopressor support (<a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> &gt;10 mcg/kg per minute, <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> &gt;0.25 mcg/kg per minute, or <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a> &gt;2 mcg/kg per minute) had decreased factor Xa activity compared to both intensive care unit (ICU) patients who did not require vasopressors and routine postoperative control patients. The clinical significance of the decrease in plasma factor Xa levels was not determined.</p><p>The authors of the study suggested that patients might need higher doses of LMW heparin to attain adequate thrombosis prophylaxis. Another approach is to change subcutaneous medications to an intravenous form whenever a patient is receiving vasopressor therapy.</p><p class="headingAnchor" id="H14"><span class="h2">Frequent re-evaluation</span><span class="headingEndMark"> — </span>Critically ill patients may undergo a second hemodynamic insult which necessitates a change in vasopressor or inotrope management. The dosage of a given agent should not simply be increased because of persistent or worsening hypotension without reconsideration of the patient's clinical situation and the appropriateness of the current strategy.</p><p class="headingAnchor" id="H15"><span class="h1">ADRENERGIC AGENTS</span><span class="headingEndMark"> — </span>Adrenergic agents, such as <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>, <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a>, <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a>, and <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a>, are the most commonly used vasopressor and inotropic drugs in critically ill patients  (<a class="graphic graphic_table graphicRef99963" href="/z/d/graphic/99963.html" rel="external">table 1</a>). These agents manifest different receptor selectivity and clinical effects  (<a class="graphic graphic_table graphicRef63100" href="/z/d/graphic/63100.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H376789843"><span class="h2">Norepinephrine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">Norepinephrine</a> (Levophed) acts on both alpha-1 and beta-1 adrenergic receptors, thus producing potent vasoconstriction as well as a modest increase in cardiac output [<a href="#rid7">7</a>]. A reflex bradycardia usually occurs in response to the increased mean arterial pressure (MAP), such that the mild chronotropic effect is canceled out and the heart rate remains unchanged or even decreases slightly. Norepinephrine is the preferred vasopressor for the treatment of septic shock. (See <a class="local">'Choice of agent in septic shock'</a> below and  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Phenylephrine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">Phenylephrine</a> (Neo-Synephrine) has purely alpha-adrenergic agonist activity and therefore results in vasoconstriction with minimal cardiac inotropy or chronotropy. MAP is augmented by raising systemic vascular resistance (SVR) [<a href="#rid19">19</a>]. The drug is useful in the setting of hypotension with an SVR &lt;700 dynes x sec/cm<sup>5</sup> (eg, hyperdynamic sepsis, neurologic disorders, anesthesia-induced hypotension). A potential disadvantage of phenylephrine is that it may decrease stroke volume, so it is reserved for patients in whom <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> is contraindicated due to arrhythmias or who have failed other therapies.</p><p>Although SVR elevation increases cardiac afterload, most studies document that cardiac output (CO) is either maintained or actually increased among patients without pre-existing cardiac dysfunction [<a href="#rid4">4,20</a>]. The drug is contraindicated if the SVR is &gt;1200 dynes x sec/cm<sup>5</sup>.</p><p class="headingAnchor" id="H18"><span class="h2">Epinephrine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">Epinephrine</a> (Adrenalin) has potent beta-1 adrenergic receptor activity and moderate beta-2 and alpha-1 adrenergic receptor effects. Clinically, low doses of epinephrine increase CO because of the beta-1 adrenergic receptor inotropic and chronotropic effects, while the alpha adrenergic receptor-induced vasoconstriction is often offset by the beta-2 adrenergic receptor vasodilation. The result is an increased CO, with decreased SVR and variable effects on the MAP [<a href="#rid3">3</a>].However, at higher epinephrine doses the alpha-adrenergic receptor effect predominates, producing increased SVR in addition to an increased CO. Epinephrine is most often used for the treatment of anaphylaxis, as a second line agent (after <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a>) in septic shock, and for management of hypotension following coronary artery bypass grafting.</p><p>Other disadvantages of <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> include dysrhythmias (due to beta-1 adrenergic receptor stimulation) and splanchnic vasoconstriction. The degree of splanchnic vasoconstriction appears to be greater with epinephrine than with equipotent doses of <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> or <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> in patients with severe shock [<a href="#rid21">21</a>], although the clinical importance of this is unclear.</p><p class="headingAnchor" id="H19"><span class="h2">Ephedrine</span><span class="headingEndMark"> — </span>Similar to <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a> acts primarily on alpha- and beta-adrenergic receptors, but with less potency. It also has an effect by leading to release of endogenous <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a>. Ephedrine is rarely used except in the setting of post-anesthesia-induced hypotension.</p><p class="headingAnchor" id="H20"><span class="h2">Dopamine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">Dopamine</a> (Intropin) has a variety of effects depending upon the dose range administered. It is most often used as a second-line alternative to <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> in patients with absolute or relative bradycardia and a low risk of tachyarrhythmias. Weight-based administration of dopamine can achieve quite different serum drug concentrations in different individuals [<a href="#rid22">22</a>], but the following provides an approximate description of effects:</p><p class="bulletIndent1"><span class="glyph">●</span>At doses of 1 to 2 mcg/kg per minute, <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> acts predominantly on dopamine-1 receptors in the renal, mesenteric, cerebral, and coronary beds, resulting in selective vasodilation. Some reports suggest that dopamine increases urine output by augmenting renal blood flow and glomerular filtration rate, and natriuresis by inhibiting aldosterone and renal tubular sodium transport [<a href="#rid23">23-25</a>]. These effects may be blunted by <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> and other butyrophenones [<a href="#rid25">25</a>]. However, the clinical significance of these phenomena is unclear, and some patients may develop hypotension at these low doses [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/2368.html" rel="external">"Renal actions of dopamine"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At 5 to 10 mcg/kg per minute, <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> also stimulates beta-1 adrenergic receptors and increases cardiac output, predominantly by increasing stroke volume with variable effects on heart rate [<a href="#rid27">27</a>]. Doses between 2 and 5 mcg/kg per minute have variable effects on hemodynamics in individual patients: vasodilation is often balanced by increased stroke volume, producing little net effect upon systemic blood pressure. Some mild alpha adrenergic receptor activation increases SVR, and the sum of these effects is an increase in MAP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At doses &gt;10 mcg/kg per minute, the predominant effect of <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> is to stimulate alpha-adrenergic receptors and produce vasoconstriction with an increased SVR [<a href="#rid27">27,28</a>]. However, the overall alpha-adrenergic receptor effect of dopamine is weaker than that of <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a>, and the beta-1 adrenergic receptor stimulation of dopamine at doses &gt;2 mcg/kg per minute can result in dose-limiting dysrhythmias.</p><p></p><p>In practical terms, the dose-dependent effects of <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> mean that changing the dose of the drug is akin to switching vasopressors. Conversely, simply increasing the dose of dopamine without being cognizant of the different receptor populations activated can cause untoward results.</p><p>The usual dose range for <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> is 2 to 20 mcg/kg per minute, although doses as high as 130 mcg/kg per minute have been employed [<a href="#rid29">29</a>]. When used for cardiac failure, dopamine should be started at 2 mcg/kg per minute and then titrated to a desired physiologic effect rather than depending on the predicted pharmacologic ranges described above.</p><p class="headingAnchor" id="H21"><span class="h2">Dobutamine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">Dobutamine</a> (Dobutrex) is not a vasopressor but rather is an inotrope that causes vasodilation. Dobutamine's predominant beta-1 adrenergic receptor effect increases inotropy and chronotropy and reduces left ventricular filling pressure. In patients with heart failure this results in a reduction in cardiac sympathetic activity [<a href="#rid30">30</a>]. However, minimal alpha- and beta-2 adrenergic receptor effects result in overall vasodilation, complemented by reflex vasodilation to the increased CO. The net effect is increased CO, with decreased SVR with or without a small reduction in blood pressure.</p><p><a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">Dobutamine</a> is most frequently used in severe, medically refractory heart failure and cardiogenic shock and should not be routinely used in sepsis because of the risk of hypotension. Dobutamine does not selectively vasodilate the renal vascular bed, as <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> does at low doses. (See  <a class="medical medical_review" href="/z/d/html/3488.html" rel="external">"Inotropic agents in heart failure with reduced ejection fraction"</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Isoproterenol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">Isoproterenol</a> (Isuprel) also is primarily an inotropic and chronotropic agent rather than a vasopressor. It acts upon beta-1 adrenergic receptors and, unlike <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a>, has a prominent chronotropic effect. The drug's high affinity for the beta-2 adrenergic receptor causes vasodilation and a decrease in MAP. Therefore, its utility in hypotensive patients is limited to situations in which hypotension results from bradycardia.</p><p class="headingAnchor" id="H23"><span class="h2">Contraindications and interactions</span><span class="headingEndMark"> — </span>Several conditions or medications require avoidance of specific agents:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with cardiogenic shock, <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> is preferred over <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> as the first-line vasopressor because a subgroup analysis from a randomized trial found that patients with cardiogenic shock who received dopamine had a higher mortality than those who received norepinephrine [<a href="#rid31">31</a>]. In addition, dysrhythmias were more common in the dopamine group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with pheochromocytoma are at risk of excessive autonomic stimulation from adrenergic vasopressors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">Dobutamine</a> is contraindicated in the setting of idiopathic hypertrophic subaortic stenosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients receiving monoamine oxidase inhibitors are extremely sensitive to vasopressors and, therefore, require much lower doses.</p><p></p><p class="headingAnchor" id="H25"><span class="h1">VASOPRESSIN AND ANALOGS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">Vasopressin</a> (antidiuretic hormone) is used in the management of arginine vasopressin disorders (formerly known as diabetes insipidus) and esophageal variceal bleeding; however, it may also be helpful in the management of vasodilatory shock  (<a class="graphic graphic_table graphicRef99963" href="/z/d/graphic/99963.html" rel="external">table 1</a>). Although its precise role in vasodilatory shock remains to be defined, it is primarily used as a second-line agent in refractory vasodilatory shock, particularly septic shock or anaphylaxis that is unresponsive to <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> [<a href="#rid32">32-38</a>]. It is also used occasionally to reduce the dose of the first-line agent. <a class="drug drug_general" data-topicid="139628" href="/z/d/drug information/139628.html" rel="external">Terlipressin</a>, a vasopressin analog, has been assessed in patients with vasodilatory shock [<a href="#rid39">39-44</a>], but it is not available in the United States.</p><p>The effects of <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a> and <a class="drug drug_general" data-topicid="139628" href="/z/d/drug information/139628.html" rel="external">terlipressin</a> in vasodilatory shock (mostly septic shock) were evaluated in a systematic review that identified 10 relevant randomized trials (1134 patients) [<a href="#rid45">45</a>]. A meta-analysis of six of the trials (512 patients) compared vasopressin or terlipressin with placebo or supportive care. There was no significant improvement in short-term mortality among patients who received either vasopressin or terlipressin (40.2 versus 42.9 percent, relative risk 0.91, 95% CI 0.79-1.05). However, patients who received vasopressin or terlipressin required less <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a>. A second randomized trial compared vasopressin with norepinephrine in 409 patients with septic shock. Although vasopressin did not improve mortality or the number of kidney failure-free days, it may have been associated with a reduction in the rate of kidney failure requiring renal replacement therapy (25 versus 35 percent) [<a href="#rid46">46</a>]. Further studies are needed before vasopressin can replace norepinephrine as the first-choice agent for those with septic shock. (See <a class="local">'Choice of agent in septic shock'</a> below.)</p><p>The effects of <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a> may be dose dependent. A randomized trial compared two doses of vasopressin (0.0333 versus 0.067 IU/min) in 50 patients with vasodilatory shock who required vasopressin as a second pressor agent [<a href="#rid47">47</a>]. The higher dose was more effective at increasing the blood pressure without increasing the frequency of adverse effects in these patients. However, doses of vasopressin above 0.04 units/min have been associated with coronary and mesenteric ischemia and skin necrosis in some studies [<a href="#rid48">48-51</a>], although some of these studies were in animals and necrosis in humans may also have been due to coexisting conditions (eg, disseminated intravascular coagulation). However, doses higher than the therapeutic range (0.04 units/min) are generally avoided for this reason unless an adequate mean arterial pressure (MAP) cannot be attained with other vasopressor agents. When weaning, we generally attempt to wean off vasopressin before <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a>.</p><p>Based upon clinical experience, hypotension appears to be common following withdrawal of <a class="external" href="%2Fcontents%2Fvasopressin-drug-information%3Fsource%3Dsee_link&amp;data=02|01|Geraldine.Finlay%40wolterskluwer.com|a92ac171bc4e4bb1638708d63e64d6a5|8ac76c91e7f141ffa89c3553b2da2c17|0|0|636765000155963969&amp;sdata=aY8yfGc4RSDxlFoYlwr19qwN2Z4sCXxX5AMs0LD7JcM%3D&amp;reserved=0" target="_blank">vasopressin</a>. To avoid this, the dose can be slowly tapered by 0.01 units/minute every 30 to 60 minutes [<a href="#rid52">52,53</a>]. Data describing use of <a class="drug drug_general" data-topicid="9651" href="/z/d/drug information/9651.html" rel="external">midodrine</a> to facilitate weaning off IV <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a> are conflicting [<a href="#rid54">54,55</a>].</p><p>Other potential adverse effects of <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a> include hyponatremia, pulmonary vasoconstriction, and arginine vasopressin disorders [<a href="#rid48">48-51,56</a>]. <a class="drug drug_general" data-topicid="139628" href="/z/d/drug information/139628.html" rel="external">Terlipressin</a> appears to have a similar side effect profile to vasopressin. In a meta-analysis of four trials (431 patients) that was conducted as part of the systematic review described above, there was no significant difference in the frequency of adverse events among patients who received either vasopressin or terlipressin (10.6 versus 11.8 percent, relative risk 0.90, 95% CI 0.49-1.67) [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H24028105"><span class="h1">NONADRENERGIC AGENTS</span><span class="headingEndMark"> — </span>A number of agents produce vasoconstriction or inotropy through nonadrenergic mechanisms, including phosphodiesterase inhibitors and nitric oxide synthase inhibitors, calcium sensitizers, or angiotensin II.</p><p class="headingAnchor" id="H26"><span class="h2">PDE inhibitors</span><span class="headingEndMark"> — </span>Phosphodiesterase (PDE) inhibitors, such as inamrinone (formerly known as amrinone) and <a class="drug drug_general" data-topicid="9652" href="/z/d/drug information/9652.html" rel="external">milrinone</a>, are nonadrenergic drugs with inotropic and vasodilatory actions. In many ways, their effects are similar to those of <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> but with a lower incidence of dysrhythmias. PDE inhibitors most often are used to treat patients with impaired cardiac function and medically refractory heart failure, but their vasodilatory properties limit their use in hypotensive patients [<a href="#rid27">27</a>]. Inamrinone is no longer available in North America and most/all other countries so the only intravenous PDE inhibitor used in the US is milrinone. (See  <a class="medical medical_review" href="/z/d/html/3488.html" rel="external">"Inotropic agents in heart failure with reduced ejection fraction"</a>.)</p><p class="headingAnchor" id="H27"><span class="h2">NOS inhibitors</span><span class="headingEndMark"> — </span>Nitric oxide overproduction appears to play a major role in vasodilation induced by sepsis (see  <a class="medical medical_review" href="/z/d/html/1597.html" rel="external">"Pathophysiology of sepsis"</a>). Studies of nitric oxide synthase (NOS) inhibitors such as N-monomethyl-L-arginine (L-NMMA) in sepsis demonstrate a dose-dependent increase in systemic vascular resistance (SVR) [<a href="#rid57">57</a>]. However, cardiac index (CI) and heart rate (HR) decrease, even when patients are treated concomitantly with <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> or <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>. The increase in SVR tends to be offset by the drop in CI, such that mean arterial pressure (MAP) is only minimally augmented. The clinical utility of this class of drugs remains unproven.</p><p class="headingAnchor" id="H1440880482"><span class="h2">Calcium sensitizers</span><span class="headingEndMark"> — </span>Several agents increase myocardial contractility (eg, pimobendan, levosimendan) but conclusive evidence of improved outcomes with their use is lacking [<a href="#rid58">58,59</a>].</p><p class="headingAnchor" id="H245001153"><span class="h2">Angiotensin II</span><span class="headingEndMark"> — </span>Preliminary trials have reported an adequate vasopressor effect when <a class="drug drug_general" data-topicid="116178" href="/z/d/drug information/116178.html" rel="external">synthetic angiotensin II</a> is exogenously administered for vasodilatory shock (eg, septic shock) [<a href="#rid60">60,61</a>]. Best supporting its role as a vasopressor agent is a randomized trial of 344 patients with vasodilatory shock (80 percent had sepsis and patients had a normal cardiac output) already receiving high dose <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> or similar vasopressor equivalent [<a href="#rid62">62</a>]. When compared with placebo, angiotensin II resulted in a greater proportion of patients achieving a 10 mmHg or greater increase in the baseline mean arterial pressure (MAP) or more or an increase in the MAP to 75 mmHg or higher (70 versus 23 percent), at three hours. There was no effect on mortality or on the sequential organ failure assessment score. Serious adverse events were no different among the groups. Angiotensin II resulted in less background vasopressor use and higher heart rates but did not result in life-threatening tachyarrhythmias.</p><p>In another retrospective observational study of 50 patients with cardiac or respiratory failure requiring treatment with mechanical circulatory support devices who had vasodilatory shock, angiotensin II increased the MAP and allowed a reduction in the dose of other vasopressors without altering cardiac index or mean pulmonary artery pressure [<a href="#rid63">63</a>].</p><p>Further trials will be required to compare angiotensin II with other vasopressor agents and to examine its effects in populations other than those with vasodilatory shock before it can be routinely used as a second line agent for the treatment of shock.</p><p class="headingAnchor" id="H28"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Vasopressors and inotropic agents have the potential to cause a number of significant complications, including hypoperfusion, dysrhythmias, myocardial ischemia, local effects, and hyperglycemia. In addition, a number of drug interactions exist.</p><p class="headingAnchor" id="H29"><span class="h2">Hypoperfusion</span><span class="headingEndMark"> — </span>Excessive vasoconstriction in response to hypotension and vasopressors can produce inadequate perfusion of the extremities, mesenteric organs, or kidneys. Excessive vasoconstriction with inadequate perfusion, usually with an systemic vascular resistance (SVR) &gt;1300 dynes x sec/cm<sup>5</sup>, commonly occurs in the setting of inadequate cardiac output or inadequate volume resuscitation.</p><p>The initial findings are dusky skin changes at the tips of the fingers and/or toes, which may progress to frank necrosis with autoamputation of the digits. Compromise of the renal vascular bed may produce renal insufficiency and oliguria, while patients with underlying peripheral artery disease may develop acute limb ischemia.</p><p>Inadequate mesenteric perfusion increases the risk of gastritis, shock liver, intestinal ischemia, or translocation of gut flora with resultant bacteremia. Despite these concerns, maintenance of MAP with vasopressors appears more effective in maintaining renal and mesenteric blood flow than allowing the MAP to drop, and maintenance of MAP with vasopressors may be life-saving despite evidence of localized hypoperfusion [<a href="#rid19">19,64</a>].</p><p class="headingAnchor" id="H30"><span class="h2">Dysrhythmias</span><span class="headingEndMark"> — </span>Many vasopressors and inotropes exert powerful chronotropic effects via stimulation of beta-1 adrenergic receptors. This increases the risk of sinus tachycardia (most common), atrial fibrillation (potentially with increased atrioventricular nodal [A-V] conduction and therefore an increased ventricular response), re-entrant atrioventricular node tachycardia, or ventricular tachyarrhythmias.</p><p>Adequate volume loading may minimize the frequency or severity of dysrhythmias. Despite this, dysrhythmias often limit the dose and necessitate switching to another agent with less prominent beta-1 effects. The degree to which the agent affects the frequency of dysrhythmias was illustrated by a randomized trial of 1679 patients with shock [<a href="#rid31">31</a>]. Dysrhythmias were significantly more common among patients who received <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> than among those who received <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> (24.1 versus 12.4 percent).</p><p class="headingAnchor" id="H31"><span class="h2">Myocardial ischemia</span><span class="headingEndMark"> — </span>The chronotropic and inotropic effects of beta-adrenergic receptor stimulation can increase myocardial oxygen consumption. While there is usually coronary vasodilation in response to vasopressors [<a href="#rid65">65</a>], perfusion may still be inadequate to accommodate the increased myocardial oxygen demand. Daily electrocardiograms on patients treated with vasopressors or inotropes may screen for occult ischemia, and excessive tachycardia should be avoided because of impaired diastolic filling of the coronary arteries.</p><p class="headingAnchor" id="H32"><span class="h2">Local effects</span><span class="headingEndMark"> — </span>Peripheral extravasation of vasopressors into the surrounding connective tissue can lead to excessive local vasoconstriction with subsequent skin necrosis. To avoid this complication, vasopressors should be administered via a central vein whenever possible. If infiltration occurs, local treatment with <a class="drug drug_general" data-topicid="9767" href="/z/d/drug information/9767.html" rel="external">phentolamine</a> (5 to 10 mg in 10 mL of normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) injected subcutaneously can minimize local vasoconstriction [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H33"><span class="h2">Hyperglycemia</span><span class="headingEndMark"> — </span>Hyperglycemia may occur due to the inhibition of insulin secretion. The magnitude of hyperglycemia generally is minor and is more pronounced with <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> and <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> than <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> [<a href="#rid24">24</a>]. Monitoring of blood glucose while on vasopressors can prevent complications of untreated hyperglycemia.</p><p class="headingAnchor" id="H34"><span class="h1">CONTROVERSIES</span><span class="headingEndMark"> — </span>Several controversies exist regarding the use of vasopressors and inotropic agents in critically ill patients. Most stem from the relative paucity of large-scale studies comparing similar patient populations treated with different regimens. The development of clear definitions for the systemic inflammatory response syndrome, sepsis, and septic shock is a step forward toward comparative trials among standardized patient populations. (See  <a class="medical medical_review" href="/z/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis"</a>.)</p><p class="headingAnchor" id="H35"><span class="h2">Choice of agent in septic shock</span><span class="headingEndMark"> — </span>The optimal agent in patients with septic shock is unknown and practice varies considerably among experts. However, based upon meta-analyses of small randomized trials and observational studies, a paradigm shift in practice has occurred such that most experts prefer to avoid <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> in this population and favor <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> as the first-choice agent the details of which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults", section on 'Vasopressors'</a>.)</p><p class="headingAnchor" id="H38"><span class="h2">"Renal dose" dopamine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">Dopamine</a> selectively increases renal blood flow when administered to normal volunteers at 1 to 3 mcg/kg per minute [<a href="#rid67">67,68</a>]. Animal studies also suggest that low-dose dopamine in the setting of vasopressor-dependent sepsis helps preserve renal blood flow [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/z/d/html/2368.html" rel="external">"Renal actions of dopamine"</a> and  <a class="medical medical_review" href="/z/d/html/7224.html" rel="external">"Possible prevention and therapy of ischemic acute tubular necrosis"</a>.)</p><p>However, a beneficial effect of low or "renal dose" <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> is less proven in human patients with sepsis or other critical illness. Critically ill patients who do not have evidence of renal insufficiency or decreased urine output will develop a diuresis in response to dopamine at 2 to 3 mcg/kg per minute, with variable effects on creatinine clearance, but the benefit of this diuresis is questionable [<a href="#rid13">13,26</a>]. The intervention is not entirely benign because hypotension and tachycardia may ensue. One small study demonstrated that the addition of low dose dopamine to patients receiving other vasopressors increases splanchnic blood flow but does not alter other indices of mesenteric perfusion, such as gastric intramucosal pH (pHi) [<a href="#rid70">70</a>].</p><p>At present, there are no data to support the routine use of low dose <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> to prevent or treat acute renal failure or mesenteric ischemia. In general, the most effective means of protecting the kidneys in the setting of septic shock appears to be the maintenance of mean arterial pressure (MAP) &gt;60 mmHg while attempting to avoid excessive vasoconstriction (ie, the systemic vascular resistance [SVR] should not exceed 1300 dynes x sec/cm<sup>5</sup>) [<a href="#rid8">8,15,71,72</a>].</p><p class="headingAnchor" id="H39"><span class="h2">Optimal dosage</span><span class="headingEndMark"> — </span>Optimal dosing is poorly defined. Most experts use a physiological target such as MAP and signs of adequate organ perfusion (eg, urine output, capillary refill time, mental status). Adequate targets are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults", section on 'Monitor response'</a>.)</p><p>Although <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> doses of up to 100 mcg/min in adults are typically used in refractory shock and as salvage therapy in combination with a second vasopressor agent, there is no well-established maximum dose. Several studies have suggested improved tissue perfusion when higher doses of norepinephrine (up to 350 mcg/min) are used [<a href="#rid15">15,72</a>] but no survival benefit of high-dose norepinephrine has been conclusively proven.</p><p class="headingAnchor" id="H40"><span class="h2">Supranormal cardiac index</span><span class="headingEndMark"> — </span>Elevation of the cardiac index with inotropic agents to supranormal values (ie, &gt;4.5 L/minute per m<sup>2</sup>) potentially increases oxygen delivery to peripheral tissues. In theory, increased oxygen delivery may prevent tissue hypoxia and improve outcomes, and initial studies appeared to support this hypothesis [<a href="#rid73">73-75</a>]. However, later larger trials showed that goal-oriented hemodynamic therapy to increase either cardiac index to &gt;4.5 L/min per m<sup>2</sup> or oxygen delivery to &gt;600 to 650 mL/min per m<sup>2</sup> with volume expansion or <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> resulted in either no improvement or worsened morbidity or mortality [<a href="#rid16">16,17,76</a>]. Therefore, the routine administration of vasopressors or inotropes to improve cardiac output or oxygen delivery to supranormal levels is not advocated. (See  <a class="medical medical_review" href="/z/d/html/1623.html" rel="external">"Oxygen delivery and consumption"</a>.)</p><p>The American Thoracic Society (ATS) statement on the detection, correction, and prevention of tissue hypoxia, as well as other ATS guidelines, can be accessed through the ATS web site at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.thoracic.org%2Fstatements%2F&amp;token=Pby%2FnGkMB8TdW5V6epNUr3SRsNf6YBT3Fr3MIDgZvpZGvZXjM5qSgaeGcxqQwZtc&amp;TOPIC_ID=1619" target="_blank">www.thoracic.org/statements</a>.</p><p class="headingAnchor" id="H653804858"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111943.html" rel="external">"Society guideline links: Sepsis in children and adults"</a>.)</p><p class="headingAnchor" id="H41"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Vasopressors are a powerful class of drugs that induce vasoconstriction and elevate mean arterial pressure (MAP). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physiology</strong> – Alpha-1 adrenergic receptors induce vasoconstriction, while beta-1 receptors induce inotropy plus chronotropy, and beta-2 receptors induce vasodilation. One subtype of <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> receptor induces <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> release with subsequent vasoconstriction, although many dopamine receptors induce vasodilation. Some agents increase the sensitivity of the myocardial contractile apparatus to calcium while others cause direct vasoconstriction via angiotensin II receptor stimulation. (See <a class="local">'Physiologic mechanisms of vasoconstriction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Principles</strong> – Vasopressors are indicated for an MAP &lt;60 mmHg, or a decrease of systolic blood pressure that exceeds 30 mmHg from baseline, when either condition results in end-organ dysfunction due to hypoperfusion. (See <a class="local">'Principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Practical issues</strong> – Hypovolemia should be corrected prior to the institution of vasopressor therapy for maximum efficacy. Patients should be re-evaluated frequently once vasopressor therapy has been initiated. Common issues that arise include tachyphylaxis, which may require dose titration, and additional hemodynamic insults, which should be recognized and managed. (See <a class="local">'Practical issues'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choosing an agent</strong> – Choice of an initial agent should be based upon the suspected underlying etiology of shock (eg, <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> for cardiogenic shock without significant hypotension, <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> for septic and cardiogenic shock with hypotension, <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> for anaphylactic shock). (See <a class="local">'Practical issues'</a> above and  <a class="medical medical_review" href="/z/d/html/83.html" rel="external">"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction", section on 'Vasopressors and inotropes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Complications of vasopressor therapy include hypoperfusion (particularly affecting the extremities, mesentery or kidneys), dysrhythmias, myocardial ischemia, peripheral extravasation with skin necrosis, and hyperglycemia. (See <a class="local">'Complications'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Müllner M, Urbanek B, Havel C, et al. Vasopressors for shock. Cochrane Database Syst Rev 2004; :CD003709.</a></li><li><a class="nounderline abstract_t">AHLQUIST RP. A study of the adrenotropic receptors. Am J Physiol 1948; 153:586.</a></li><li><a class="nounderline abstract_t">ALLWOOD MJ, COBBOLD AF, GINSBURG J. Peripheral vascular effects of noradrenaline, isopropylnoradrenaline and dopamine. Br Med Bull 1963; 19:132.</a></li><li><a class="nounderline abstract_t">Williamson AP, Seifen E, Lindemann JP, Kennedy RH. WB4101- and CEC-sensitive positive inotropic actions of phenylephrine in rat cardiac muscle. Am J Physiol 1994; 266:H2462.</a></li><li><a class="nounderline abstract_t">Catt KJ, Mendelsohn FA, Millan MA, Aguilera G. The role of angiotensin II receptors in vascular regulation. J Cardiovasc Pharmacol 1984; 6 Suppl 4:S575.</a></li><li><a class="nounderline abstract_t">Lamontagne F, Richards-Belle A, Thomas K, et al. Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension: A Randomized Clinical Trial. JAMA 2020; 323:938.</a></li><li><a class="nounderline abstract_t">Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 1999; 27:639.</a></li><li><a class="nounderline abstract_t">Moran JL, O'Fathartaigh MS, Peisach AR, et al. Epinephrine as an inotropic agent in septic shock: a dose-profile analysis. Crit Care Med 1993; 21:70.</a></li><li><a class="nounderline abstract_t">Calvin JE, Driedger AA, Sibbald WJ. Does the pulmonary capillary wedge pressure predict left ventricular preload in critically ill patients? Crit Care Med 1981; 9:437.</a></li><li><a class="nounderline abstract_t">Packman MI, Rackow EC. Optimum left heart filling pressure during fluid resuscitation of patients with hypovolemic and septic shock. Crit Care Med 1983; 11:165.</a></li><li><a class="nounderline abstract_t">Datar S, Gutierrez E, Schertz A, Vachharajani V. Safety of Phenylephrine Infusion Through Peripheral Intravenous Catheter in the Neurological Intensive Care Unit. J Intensive Care Med 2018; 33:589.</a></li><li><a class="nounderline abstract_t">Ballieu P, Besharatian Y, Ansari S. Safety and Feasibility of Phenylephrine Administration Through a Peripheral Intravenous Catheter in a Neurocritical Care Unit. J Intensive Care Med 2021; 36:101.</a></li><li><a class="nounderline abstract_t">Lherm T, Troché G, Rossignol M, et al. Renal effects of low-dose dopamine in patients with sepsis syndrome or septic shock treated with catecholamines. Intensive Care Med 1996; 22:213.</a></li><li><a class="nounderline abstract_t">Unverferth DA, Blanford M, Kates RE, Leier CV. Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med 1980; 69:262.</a></li><li><a class="nounderline abstract_t">Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993; 103:1826.</a></li><li><a class="nounderline abstract_t">Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 1995; 333:1025.</a></li><li><a class="nounderline abstract_t">Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330:1717.</a></li><li><a class="nounderline abstract_t">Dörffler-Melly J, de Jonge E, Pont AC, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002; 359:849.</a></li><li><a class="nounderline abstract_t">Gregory JS, Bonfiglio MF, Dasta JF, et al. Experience with phenylephrine as a component of the pharmacologic support of septic shock. Crit Care Med 1991; 19:1395.</a></li><li><a class="nounderline abstract_t">Yamazaki T, Shimada Y, Taenaka N, et al. Circulatory responses to afterloading with phenylephrine in hyperdynamic sepsis. Crit Care Med 1982; 10:432.</a></li><li><a class="nounderline abstract_t">De Backer D, Creteur J, Silva E, Vincent JL. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med 2003; 31:1659.</a></li><li><a class="nounderline abstract_t">MacGregor DA, Smith TE, Prielipp RC, et al. Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology 2000; 92:338.</a></li><li><a class="nounderline abstract_t">Goldberg LI. Dopamine--clinical uses of an endogenous catecholamine. N Engl J Med 1974; 291:707.</a></li><li><a class="nounderline abstract_t">HORWITZ D, FOX SM 3D, GOLDBERG LI. Effects of Dopamine in man. Circ Res 1962; 10:237.</a></li><li><a class="nounderline abstract_t">Dasta JF, Kirby MG. Pharmacology and therapeutic use of low-dose dopamine. Pharmacotherapy 1986; 6:304.</a></li><li><a class="nounderline abstract_t">Duke GJ, Briedis JH, Weaver RA. Renal support in critically ill patients: low-dose dopamine or low-dose dobutamine? Crit Care Med 1994; 22:1919.</a></li><li><a class="nounderline abstract_t">Löllgen H, Drexler H. Use of inotropes in the critical care setting. Crit Care Med 1990; 18:S56.</a></li><li><a class="nounderline abstract_t">Steel, A, Bihari, D . Choice of catecholamine: does it matter? Curr Opin Crit Care 2000; 6:347.</a></li><li><a class="nounderline abstract_t">Hannemann L, Reinhart K, Grenzer O, et al. Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in septic shock. Crit Care Med 1995; 23:1962.</a></li><li><a class="nounderline abstract_t">Al-Hesayen A, Azevedo ER, Newton GE, Parker JD. The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure. J Am Coll Cardiol 2002; 39:1269.</a></li><li><a class="nounderline abstract_t">De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779.</a></li><li><a class="nounderline abstract_t">Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med 2004; 30:1276.</a></li><li><a class="nounderline abstract_t">Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31:1752.</a></li><li><a class="nounderline abstract_t">Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29:487.</a></li><li><a class="nounderline abstract_t">Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107:2313.</a></li><li><a class="nounderline abstract_t">Kill C, Wranze E, Wulf H. Successful treatment of severe anaphylactic shock with vasopressin. Two case reports. Int Arch Allergy Immunol 2004; 134:260.</a></li><li><a class="nounderline abstract_t">Schummer C, Wirsing M, Schummer W. The pivotal role of vasopressin in refractory anaphylactic shock. Anesth Analg 2008; 107:620.</a></li><li><a class="nounderline abstract_t">McIntyre WF, Um KJ, Alhazzani W, et al. Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis. JAMA 2018; 319:1889.</a></li><li><a class="nounderline abstract_t">Albanèse J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 2005; 33:1897.</a></li><li><a class="nounderline abstract_t">Kam PC, Williams S, Yoong FF. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia 2004; 59:993.</a></li><li><a class="nounderline abstract_t">O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002; 359:1209.</a></li><li><a class="nounderline abstract_t">Leone M, Albanèse J, Delmas A, et al. Terlipressin in catecholamine-resistant septic shock patients. Shock 2004; 22:314.</a></li><li><a class="nounderline abstract_t">Rodríguez-Núñez A, Fernández-Sanmartín M, Martinón-Torres F, et al. Terlipressin for catecholamine-resistant septic shock in children. Intensive Care Med 2004; 30:477.</a></li><li><a class="nounderline abstract_t">Morelli A, Rocco M, Conti G, et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 2004; 30:597.</a></li><li><a class="nounderline abstract_t">Polito A, Parisini E, Ricci Z, et al. Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis. Intensive Care Med 2012; 38:9.</a></li><li><a class="nounderline abstract_t">Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. JAMA 2016; 316:509.</a></li><li><a class="nounderline abstract_t">Torgersen C, Dünser MW, Wenzel V, et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med 2010; 36:57.</a></li><li><a class="nounderline abstract_t">Malay MB, Ashton JL, Dahl K, et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004; 32:1327.</a></li><li><a class="nounderline abstract_t">Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med 2002; 30:1899.</a></li><li><a class="nounderline abstract_t">Leather HA, Segers P, Berends N, et al. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 2002; 30:2548.</a></li><li><a class="nounderline abstract_t">Dünser MW, Mayr AJ, Tür A, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 2003; 31:1394.</a></li><li><a class="nounderline abstract_t">Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877.</a></li><li><a class="nounderline abstract_t">Jeon K, Song JU, Chung CR, et al. Incidence of hypotension according to the discontinuation order of vasopressors in the management of septic shock: a prospective randomized trial (DOVSS). Crit Care 2018; 22:131.</a></li><li><a class="nounderline abstract_t">Basiouny M, Samir G, Ibrahim A, Mahmoud M. Using of Oral Midodrine in Weaning of Intravenous Vasopressors in Patients with Septic Shock Admitted to ICU. QJM 2023; 116.</a></li><li><a class="nounderline abstract_t">Hafez H, Nashed S, Morkos FWahab W.. Midodrine as Adjunction Support for Weaning off Norepinephrine in Septic Shock. QJM 2023; 116.</a></li><li><a class="nounderline abstract_t">Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 2021; 49:e1063.</a></li><li><a class="nounderline abstract_t">Petros A, Lamb G, Leone A, et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994; 28:34.</a></li><li><a class="nounderline abstract_t">Landoni G, Lomivorotov VV, Alvaro G, et al. Levosimendan for Hemodynamic Support after Cardiac Surgery. N Engl J Med 2017.</a></li><li><a class="nounderline abstract_t">Mehta RH, Leimberger JD, van Diepen S, et al. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. N Engl J Med 2017.</a></li><li><a class="nounderline abstract_t">Antonucci E, Gleeson PJ, Annoni F, et al. Angiotensin II in Refractory Septic Shock. Shock 2017; 47:560.</a></li><li><a class="nounderline abstract_t">Chawla LS, Busse L, Brasha-Mitchell E, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care 2014; 18:534.</a></li><li><a class="nounderline abstract_t">Khanna A, English SW, Wang XS, et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med 2017; 377:419.</a></li><li><a class="nounderline abstract_t">Wieruszewski PM, Seelhammer TG, Barreto EF, et al. Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support. J Intensive Care Med 2023; 38:464.</a></li><li><a class="nounderline abstract_t">Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994; 272:1354.</a></li><li><a class="nounderline abstract_t">Bohr DF. Adrenergic receptors in coronary arteries. Ann N Y Acad Sci 1967; 139:799.</a></li><li><a class="nounderline abstract_t">Peters, JI, Utset, OM. Vasopressors in shock management: Choosing and using wisely. J Crit Illness 1989; 4:62.</a></li><li><a class="nounderline abstract_t">Hollenberg NK, Adams DF, Mendell P, et al. Renal vascular responses to dopamine: haemodynamic and angiographic observations in normal man. Clin Sci Mol Med 1973; 45:733.</a></li><li><a class="nounderline abstract_t">D'Orio V, el Allaf D, Juchmès J, Marcelle R. The use of low doses of dopamine in intensive care medicine. Arch Int Physiol Biochim 1984; 92:S11.</a></li><li><a class="nounderline abstract_t">Schaer GL, Fink MP, Parrillo JE. Norepinephrine alone versus norepinephrine plus low-dose dopamine: enhanced renal blood flow with combination pressor therapy. Crit Care Med 1985; 13:492.</a></li><li><a class="nounderline abstract_t">Meier-Hellmann A, Bredle DL, Specht M, et al. The effects of low-dose dopamine on splanchnic blood flow and oxygen uptake in patients with septic shock. Intensive Care Med 1997; 23:31.</a></li><li><a class="nounderline abstract_t">Meadows D, Edwards JD, Wilkins RG, Nightingale P. Reversal of intractable septic shock with norepinephrine therapy. Crit Care Med 1988; 16:663.</a></li><li><a class="nounderline abstract_t">Redl-Wenzl EM, Armbruster C, Edelmann G, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med 1993; 19:151.</a></li><li><a class="nounderline abstract_t">Shoemaker WC, Kram HB, Appel PL. Therapy of shock based on pathophysiology, monitoring, and outcome prediction. Crit Care Med 1990; 18:S19.</a></li><li><a class="nounderline abstract_t">Russell JA, Phang PT. The oxygen delivery/consumption controversy. Approaches to management of the critically ill. Am J Respir Crit Care Med 1994; 149:533.</a></li><li><a class="nounderline abstract_t">Tuchschmidt J, Fried J, Astiz M, Rackow E. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 1992; 102:216.</a></li><li><a class="nounderline abstract_t">Alía I, Esteban A, Gordo F, et al. A randomized and controlled trial of the effect of treatment aimed at maximizing oxygen delivery in patients with severe sepsis or septic shock. Chest 1999; 115:453.</a></li></ol></div><div id="topicVersionRevision">Topic 1619 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15266497" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Vasopressors for shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18882199" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A study of the adrenotropic receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14012200" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Peripheral vascular effects of noradrenaline, isopropylnoradrenaline and dopamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7912902" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : WB4101- and CEC-sensitive positive inotropic actions of phenylephrine in rat cardiac muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6083400" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The role of angiotensin II receptors in vascular regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32049269" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199548" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420733" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Epinephrine as an inotropic agent in septic shock: a dose-profile analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7226863" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Does the pulmonary capillary wedge pressure predict left ventricular preload in critically ill patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6831886" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Optimum left heart filling pressure during fluid resuscitation of patients with hypovolemic and septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28569131" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Safety of Phenylephrine Infusion Through Peripheral Intravenous Catheter in the Neurological Intensive Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31757173" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Safety and Feasibility of Phenylephrine Administration Through a Peripheral Intravenous Catheter in a Neurocritical Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8727434" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Renal effects of low-dose dopamine in patients with sepsis syndrome or septic shock treated with catecholamines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7405947" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Tolerance to dobutamine after a 72 hour continuous infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8404107" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7675044" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7993413" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Elevation of systemic oxygen delivery in the treatment of critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11897286" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1935160" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Experience with phenylephrine as a component of the pharmacologic support of septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7083867" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Circulatory responses to afterloading with phenylephrine in hyperdynamic sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12794401" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10691218" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pharmacokinetics of dopamine in healthy male subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4604342" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dopamine--clinical uses of an endogenous catecholamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14449132" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effects of Dopamine in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3547350" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pharmacology and therapeutic use of low-dose dopamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7988127" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Renal support in critically ill patients: low-dose dopamine or low-dose dobutamine?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2136722" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Use of inotropes in the critical care setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Choice of catecholamine: does it matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7497718" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11955843" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20200382" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of dopamine and norepinephrine in the treatment of shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15103461" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Role of vasopressin in the management of septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12794416" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Circulating vasopressin levels in septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11373409" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12732600" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15178897" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Successful treatment of severe anaphylactic shock with vasopressin. Two case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18633042" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The pivotal role of vasopressin in refractory anaphylactic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29801010" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148457" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15488059" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Vasopressin and terlipressin: pharmacology and its clinical relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11955542" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Terlipressin for norepinephrine-resistant septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15377885" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Terlipressin in catecholamine-resistant septic shock patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767584" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Terlipressin for catecholamine-resistant septic shock in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14673520" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22127480" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27483065" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19756505" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187515" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12163813" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Skin necrosis after extravasation of low-dose vasopressin administered for septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12441768" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12771608" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18305265" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Vasopressin versus norepinephrine infusion in patients with septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29784057" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Incidence of hypotension according to the discontinuation order of vasopressors in the management of septic shock: a prospective randomized trial (DOVSS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Using of Oral Midodrine in Weaning of Intravenous Vasopressors in Patients with Septic Shock Admitted to ICU</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Midodrine as Adjunction Support for Weaning off Norepinephrine in Septic Shock</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34605781" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7509259" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effects of a nitric oxide synthase inhibitor in humans with septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28320259" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Levosimendan for Hemodynamic Support after Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28316276" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27879559" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Angiotensin II in Refractory Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25286986" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28528561" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Angiotensin II for the Treatment of Vasodilatory Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36524274" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7933396" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5232343" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Adrenergic receptors in coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Vasopressors in shock management: Choosing and using wisely</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4760032" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Renal vascular responses to dopamine: haemodynamic and angiographic observations in normal man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6085236" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The use of low doses of dopamine in intensive care medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3996002" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Norepinephrine alone versus norepinephrine plus low-dose dopamine: enhanced renal blood flow with combination pressor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9037637" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The effects of low-dose dopamine on splanchnic blood flow and oxygen uptake in patients with septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3371042" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Reversal of intractable septic shock with norepinephrine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8315122" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The effects of norepinephrine on hemodynamics and renal function in severe septic shock states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2403510" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Therapy of shock based on pathophysiology, monitoring, and outcome prediction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8306058" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The oxygen delivery/consumption controversy. Approaches to management of the critically ill.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1623756" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Elevation of cardiac output and oxygen delivery improves outcome in septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027447" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A randomized and controlled trial of the effect of treatment aimed at maximizing oxygen delivery in patients with severe sepsis or septic shock.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
